Clinical Trial Update: CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating CT1190B for moderate-to-severe refractory systemic lupus erythematosus or refractory/progressive systemic sclerosis is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• CT1190B

Snippet

Sponsor: Beijing GoBroad Hospital | Conditions: Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) | Phase 1 | Status: RECRUITING